Cargando…
Antagonistic Functions of Connexin 43 during the Development of Primary or Secondary Bone Tumors
Despite research and clinical advances during recent decades, bone cancers remain a leading cause of death worldwide. There is a low survival rate for patients with primary bone tumors such as osteosarcoma and Ewing’s sarcoma or secondary bone tumors such as bone metastases from prostate carcinoma....
Autores principales: | Talbot, Julie, Dupuy, Maryne, Morice, Sarah, Rédini, Françoise, Verrecchia, Franck |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565206/ https://www.ncbi.nlm.nih.gov/pubmed/32859065 http://dx.doi.org/10.3390/biom10091240 |
Ejemplares similares
-
Sonic Hedgehog Signature in Pediatric Primary Bone Tumors: Effects of the GLI Antagonist GANT61 on Ewing’s Sarcoma Tumor Growth
por: Mullard, Mathilde, et al.
Publicado: (2020) -
The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth
por: Morice, Sarah, et al.
Publicado: (2020) -
Overexpression of the Ubiquitin Specific Proteases USP43, USP41, USP27x and USP6 in Osteosarcoma Cell Lines: Inhibition of Osteosarcoma Tumor Growth and Lung Metastasis Development by the USP Antagonist PR619
por: Lavaud, Mélanie, et al.
Publicado: (2021) -
New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
por: Danieau, Geoffroy, et al.
Publicado: (2019) -
SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression
por: Lézot, Frédéric, et al.
Publicado: (2020)